Brief: Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

BioXcel Therapeutics

01/07/2025 12:06

July 1 (Reuters) - BioXcel Therapeutics Inc BTAI.O:

BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA

BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025

BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL

Source text: ID:nGNXc8vy9N

Further company coverage: BTAI.O

 (((( Reuters.briefs@thomsonreuters.com ;));))